Gilead Sciences, the maker of the drug remdesivir shown to shorten recovery time for severely ill COVID-19 patients, says it will price the treatment course at $2,340 for people covered by government health programs in the United States and other developed countries, according to an Associated Press report. The price would be $3,120 for patients with private insurance.
The price was criticized by the consumer group Public Citizen because of the amount taxpayers invested toward the drug’s development.
